Preliminary results from a new study indicate that individual question responses within the widely-used Ocular Surface Disease Index (OSDI) symptom questionnaire can be correlated to specific clinical measures, providing eye care professionals better insight on treatment pathways. The CooperVision-supported work is being presented at the ARVO 2023 Annual Meeting this week.

Association of Clinical Signs with the Ocular Surface Disease Index: Preliminary Results from the Multicenter Neurosensory Abnormalities in ocular SurfAce Disease Study (Hom M., et al.) from the NASA Study Group probes deeper than past reports of overall OSDI score correlations. The multicenter, prospective, cross-sectional investigation assessed patients who presented for ocular surface disease care. In addition to completion of the OSDI, measures were taken for tear break-up time (TBUT), corneal fluorescein staining (CFS), lissamine green conjunctival staining (LGS), Schirmer’s test, and meibomian gland grading (MGG).

Preliminary analysis included 250 participants across 13 sites. Significant correlations were identified between decreased TBUT and difficulty reading (r=-0.166, p=0.009). Increased CFS was associated with increased frequency of gritty sensation (r=0.166, p=0.008). Decreased Schirmer’s test was associated with increased symptom frequency in windy conditions (r=-0.195, p=0.002). MGG and LGS show no significant correlations.

“These outcomes should help eye care professionals derive even more value from their OSDI questionnaires, pointing them toward potential underlying issues and treatments,” said Anna Sulley, BSc(Hons), MCOptom, FAAO, FBCLA, Director, Global Medical Affairs at CooperVision. “We’re privileged to partner with some of the top researchers and institutions in ocular science, with the aim of improving fundamental clinical practice. The works being shared at ARVO 2023 reflect this collaborative spirit.”

An additional CooperVision-supported study on display in New Orleans demonstrates the effect of ceasing and then restarting contact lens use after three months in symptomatic wearers as measured by psychophysical responses to repetitive cooling stimuli.

Click HERE for the full press release.

SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology^™ spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Meeting in New Orleans.

Most prominent is the reporting of 42-month data from the company’s pivotal CYPRESS study extension. Results reinforced the safety and efficacy of Diffusion Optics Technology™ spectacle lenses in children aged 6–10 at the study’s start. The latest investigation re-enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial to generate six additional months of data. Outcomes again demonstrated statistically significant improvements in axial length (AL) and cycloplegic spherical equivalent refraction (cSER) between the test and control groups.

Separate work calculated age-independent myopia AL growth to evaluate Diffusion Optics Technology^™ spectacle lens efficacy. Because AL growth occurs even in persistently emmetropic eyes as a child develops and is most rapid before preadolescence, deriving an age-adjusted measure is valuable for clinicians and researchers. Physiological AL growth was determined based on age-matched emmetropic eye growth data from the Orinda Longitudinal Study of Myopia, then compared to AL growth observed in the original three-year CYPRESS study. Children in the test lens group showed 0.23 mm (73%, p=0.003) less pathological AL change than the control group (test: 0.08 ± 0.06 mm; control: 0.31 ± 0.05 mm).

“The extensive and rigorous science we are communicating at ARVO 2023 demonstrates the depth of our commitment to advancing myopia control, while also building additional confidence in the efficacy, safety, and overall performance of Diffusion Optics Technology^™ spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision.

In addition to the featured CYPRESS presentations, SightGlass Vision and its research partners will display several scientific posters at the meeting. A study from the Centre for Ocular Research & Education (CORE) shows that Diffusion Optics Technology^™ spectacle lenses have no significant effect on accommodative lag after short-term wear. Work from Indiana University suggests that Diffusion Optics Technology^™ contrast-reducing micro-dots do not limit high quality spatial details and good visual performance, while another Indiana investigation concludes that wearers are unlikely to notice substantial contrast decreases when looking through the spectacle lens treatment zone.

A SightGlass team also examined the effect of social restrictions during the COVID-19 pandemic on myopia progression in North American children who participated in the CYPRESS study.

Spectacle lenses with SightGlass Vision™ Diffusion Optics Technology™ use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent-protected technology with clinically proven efficacy made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.

Click HERE for the full press release.